← Back to headlines
Silence Therapeutics Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential
Silence Therapeutics plc (SLN) has been initiated at an 'Overweight' rating by an analyst who emphasizes the potential of its siRNA pipeline.
30 Jun, 13:06 — 30 Jun, 13:06
Sources
Showing 1 of 1 sources
